SavedAdd your journal

Journals / Tüberküloz ve Toraks / 2011 / Cilt: 59 - Sayı: 4

Cardiovascular biomarkers in clinical practice of sleep apnea

Uyku apnesinin klinik uygulamasında kardiyovasküler biyobelirteçler

Neşe DURSUNOĞLU
Dursun DURSUNOĞLU
Pages
402–408
Publication Date
2022-11-03
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In the present review, some cardiovascular biomarkers such as serum C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-α), interleukins, adiponectin, heart-type fatty acid binding protein (hFABP) and brain (B-type) natriuretic peptide (BNP), and their clinical importance were reviewed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Obstructive sleep apnea syndrome (OSAS) leads to cardiovascular complications such as coronary artery disease, left/right ventricular hypertrophy and dysfunction, heart failure, systemic and pulmonary hypertension, arrhythmias and stroke; and these all cardiovascular complications increase morbidity and mortality of OSAS.
📊
Key Findings & Data:Increased sympathetic activity by hypoxemia and endotelial dysfunction play a role in cardiovascular complications.
💡
Conclusion & Impact:In the present review, some cardiovascular biomarkers such as serum C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-α), interleukins, adiponectin, heart-type fatty acid binding protein (hFABP) and brain (B-type) natriuretic peptide (BNP), and their clinical importance were reviewed.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Obstructive sleep apnea syndrome (OSAS) leads to cardiovascular complications such as coronary artery disease, left/right ventricular hypertrophy and dysfunction, heart failure, systemic and pulmonary hypertension, arrhythmias and stroke; and these all cardiovascular complications increase morbidity and mortality of OSAS. However, Cheyne-Stokes respiration, central and obstructive apneas may occur in the patient with heart failure. Increased sympathetic activity by hypoxemia and endotelial dysfunction play a role in cardiovascular complications. Some cardiovascular biomarkers have a role in early diagnosis, treatment and prognosis. In the present review, some cardiovascular biomarkers such as serum C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-α), interleukins, adiponectin, heart-type fatty acid binding protein (hFABP) and brain (B-type) natriuretic peptide (BNP), and their clinical importance were reviewed.

Özet

Obstrüktif uyku apne sendromu (OUAS), koroner arter hastalığı, sol/sağ ventrikül hipertrofisi ve disfonksiyonu, kalp yetmezliği, sistemik ve pulmoner hipertansiyon, aritmiler ve inme gibi kardiyovasküler komplikasyonlara neden olmakta ve tüm bu olaylar ise OUAS'ın mortalite ve morbiditesini artırmaktadır. Ayrıca, kalp yetmezliği olan hastalarda Cheyne-Stokes solunumu ve santral apnelerin yanı sıra obstrüktif apneler de gelişebilmektedir. Hipoksi sonucu artmış sempatik sistem aktivitesi ve endotel disfonksiyonu kardiyovasküler komplikasyonlarda rol oynamaktadır. Bazı kardiyovasküler biyobelirteçler erken tanı, tedavi ve prognozda önem taşımaktadır. Bu derlemede, kardiyovasküler biyobelirteçlerden serum C-reaktif protein (CRP), tümör nekroz faktörü-alfa (TNF-α), interlökinler, adiponektin, kalp tipi-yağ asidi bağlayıcı protein (Heart-type fatty acid binding protein; hFABP) ve beyin (brain) natriüretik peptid (BNP) düzeyleri ile uyku rutinindeki klinik önemleri gözden geçirilmiştir.

🔖

Cite This Article

DURSUNOĞLU, N., DURSUNOĞLU, D. (2022). Cardiovascular biomarkers in clinical practice of sleep apnea. Tüberküloz ve Toraks, Cilt: 59 - Sayı: 4, 402–408. https://ajindex.com/articles/619037

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Lattimore JD, Celermajer DS, Wilcow I. Obstructive sleep apnea and cardiovascular disease. J Am Coll Cardiol 2003; 41: 1429-37
  2. Dursunoglu D, Dursunoglu N. Cardiovascular diseases in obstructive sleep apnea. Tuberk Toraks 2006; 54: 382-96
  3. Dursunoglu N, Dursunoglu D. Obstructive sleep apnea syndrome, endothelial dysfunction and coronary atherosclerosis. Tuberk Toraks 2005; 53: 299-306
  4. Peker Y, Hedner J, Norum J, Kraiczi H, Carlson J. Increased incidence of cardiovascular disease in middle-aged men with obstructive sleep apnea: a 7-year follow-up. Am J Respir Crit Care Med 2002; 166: 159-65
  5. Doherty LS, Kiely JL, Swan V, McNicholas WT. Long-term effects of nasal continuous positive airway pressure therapy on cardiovascular outcomes in sleep apnea syndrome. Chest 2005; 127: 2076-84
  6. Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in “active” coronary artery disease. Am J Cardiol 1990; 65: 168-72
  7. Yamashita H, Shimada K, Seki E, Mokuno H, Daida H. Concentrations of interleukins, interferon, and C-reactive protein in stable and unstable angina pectoris. Am J Cardiol 2003; 91: 133-6
  8. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB; European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997; 349: 462-6
  9. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-65
  10. Shah SH, Newby LK. C-reactive protein: a novel marker of cardiovascular risk. Cardiology in Review 2003; 11: 169-79
  11. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-74
  12. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-43
  13. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al. Markers of imflammation and cardiovascular disease: application to clinical and public health practice: a statement for health-care professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511
  14. Alonso-Martinez JL, Llorente-Diez B, Echegaray-Agara M, Olaz-Preciado F, Urbieta-Echezarreta M, Gonzalez-Arencibia C. C-reactive protein as a pre